lung-cancer

Molecular subtype of small cell lung cancer predicts and drives resistance to a newly approved immunotherapy

Small cell lung cancer (SCLC) is one of the most aggressive cancers, and new treatment options have been desperately needed. Tarlatamab — a bispecific T-cell engager targeting DLL3 — was recently approved for relapsed SCLC, representing a real advance. But responses vary widely and resistance eventually emerges in most patients.

This study used circulating chromatin analysis (liquid biopsy) to infer SCLC molecular subtype from blood samples, finding that the transcription factor subtype (ASCL1, NEUROD1, or POU2F3) predicts who responds to tarlatamab. More strikingly, they found evidence that treatment can cause tumors to switch subtypes — a form of resistance that escapes therapeutic pressure by changing identity.

These findings have immediate clinical relevance: subtype profiling could guide patient selection, and monitoring for subtype switching could detect early resistance.

Key Findings

SCLC transcription factor subtypes (ASCL1, NEUROD1, POU2F3) predict tarlatamab response
Subtype can be inferred non-invasively from circulating chromatin (liquid biopsy)
Tarlatamab treatment can induce subtype switching as a resistance mechanism
Subtype switching was documented at the point of clinical resistance
First evidence of therapy-driven lineage plasticity as a resistance mechanism in SCLC

Implications

Subtype profiling should be considered in tarlatamab treatment planning and monitoring. The discovery of treatment-induced subtype switching opens a new research direction: understanding and blocking lineage plasticity could prevent or delay resistance. This also raises the possibility of sequential or combination strategies targeting multiple subtypes.

Caveats

Preprint — not peer reviewed. Based on abstract only; sample sizes and statistical details not available. Liquid biopsy subtype inference methods need clinical validation. Subtype switching was observed but causal mechanisms are not fully established.

Source: bioRxiv — 2026-04-08

Landmark DCIS trial, CRC microbiome & AML combos

Two themes cut across this week’s 236 posts. The first is de-escalation: researchers are building rigorous evidence that patients can safely do less — skip lymph node surgery, forgo radiotherapy, watch pre-invasive lesions instead of cutting them out. The landmark result here is a randomized trial confirming that active surveillance

Colorectal Cancer Microbiome Discovery Platform

Analysis of 9,000+ patients revealed that only colorectal cancer — not other cancer types — consistently harbors distinct microbial communities, suggesting the gut microbiome has a unique relationship with colorectal carcinogenesis that could be exploited for diagnostics and treatment.

GBM Tumor Microenvironment Drug Target Atlas

Non-cancerous brain support cells were found to promote glioblastoma growth through paracrine signaling, and blocking this communication dramatically slowed tumor growth — revealing that GBM's microenvironment contains targetable vulnerabilities that are being systematically overlooked by drug…

BET Inhibitor Target Selectivity Database

BRD2 and BRD4 have fundamentally distinct functions — BRD2 prepares genes for activation while BRD4 triggers transcription — meaning that pan-BET inhibitors have been disrupting gene regulation in counterproductive ways, and the field now needs selective BRD4 inhibitors.